Enfiera 500mg Injection

About Enfiera 500mg Injection

Enfiera 500mg Injection contains Rituximab, a targeted monoclonal antibody therapy that belongs to the anti-CD20 class of medications. It is used to treat a variety of cancers and autoimmune disorders, including non-Hodgkins lymphoma, chronic lymphocytic leukemia (CLL), moderate-to-severe rheumatoid arthritis in combination with methotrexate, granulomatosis with polyangiitis, microscopic polyangiitis, and moderate-to-severe pemphigus vulgaris. Rituximab works by targeting CD20 proteins on specific B-lymphocytes, helping to destroy abnormal or overactive immune cells that contribute to these conditions. Enfiera 500mg Injection should not be used by patients who are allergic to Rituximab or any of its ingredients, have severe active infections, or have a significantly weakened immune system. Before starting treatment, patients should inform their healthcare provider about any history of heart disease, heart failure, breathing difficulties, or previous hepatitis B infection, as the virus may reactivate during treatment and lead to serious complications. Pregnancy and breastfeeding are generally not recommended while receiving this medication, and women of childbearing potential should use effective contraception during treatment and for 12 months after the final dose. Common side effects may include infections, low red blood cell counts, dizziness, swelling of the face or body, itchy skin, diarrhea, excessive sweating, and changes in blood pressure. Serious infusion-related reactions can occur during or within 24 hours of administration, and patients should seek immediate medical attention if they experience symptoms such as chest pain, breathing difficulties, severe skin reactions, vomiting, headache, throat swelling, or sudden changes in blood pressure. Regular monitoring throughout treatment helps ensure the safe and effective use of Enfiera 500mg Injection.

Targeted Therapy for Non-Hodgkin's Lymphoma

Enfiera 500mg Injection is a targeted therapy designed for patients with non-Hodgkin's lymphoma (NHL). Its active component, rituximab, binds specifically to cancer cells, helping to destroy them while minimizing harm to healthy tissue. This precise action makes it a preferred choice in lymphoma management, enhancing the chances of remission and improving patients' quality of life.


Quality Assurance and Safe Handling

Manufactured in India, Enfiera 500mg Injection meets strict quality standards. The product is delivered in secure packaging with one injection per box and an extended expiration date until 2028, ensuring long-term usability. Proper refrigeration is essential to maintain the injection's stability and therapeutic effectiveness throughout its shelf life.


Usage and Administration Guidelines

Enfiera 500mg Injection is intended for administration by healthcare professionals in clinical settings. The precise dosage and regimen depend on individual patient needs and must follow medical guidelines. The injection is commonly part of a comprehensive cancer care protocol, often in combination with other treatments as determined by an oncologist.